The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women

Breast Cancer Research

Volumn 7, Issue 3, 2005, Pages

  Montgomery, Karen G ^a   Chang, Jiun Horng ^b   Gertig, Dorota M ^b   Dite, Gillian S ^b   McCredie, Margaret R ^c,e   Giles, Graham G ^d   Southey, Melissa C ^b   Hopper, John L ^b   Campbell, Ian G ^a  

^a Victorian Breast Cancer Research Consortium   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d CANCER EPIDEMIOLOGY CENTRE   (Australia)

^e Epidemiology Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID RECEPTOR COACTIVATOR 3; ACYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; NUCLEAR RECEPTOR COACTIVATOR 3; ONCOPROTEIN; TRANSACTIVATOR PROTEIN;

ADULT; AIB1 GENE; ARTICLE; AUSTRALIAN; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; RISK ASSESSMENT; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; AUSTRALIA; BREAST TUMOR; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETICS; ONSET AGE; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; TRINUCLEOTIDE REPEAT;

ACETYLTRANSFERASES; ADULT; AGE OF ONSET; AUSTRALIA; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISTONE ACETYLTRANSFERASES; HUMANS; ONCOGENE PROTEINS; POLYMORPHISM, GENETIC; RISK FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRINUCLEOTIDE REPEATS;

EID: 33644800083     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1009     Document Type: Article

References (9)

1. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Brown M, Hunter DJ: Polymorphic repeat in AIB1 does not alter breast cancer risk. Breast Cancer Res. 2000, 2: 378-385. 10.1186/bcr82.
2. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997, 277: 965-968. 10.1126/science.277.5328.965.
3. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D, et al: Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 2001, 61: 5420-5424.
4. Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Meltzer P, Theillet C: In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res. 1998, 4: 2925-2929.
5. Chamberlain NL, Driver ED, Miesfeld RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994, 22: 3181-3186.
6. McCredie MR, Dite GS, Giles GG, Hopper JL: Breast cancer in Australian women under the age of 40. Cancer Causes Control. 1998, 9: 189-198. 10.1023/A:1008886328352.
7. Kadouri L, Kote-Jarai Z, Easton DF, Hubert A, Hamoudi R, Glaser B, Abeliovich D, Peretz T, Eeles RA: Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Int J Cancer. 2004, 108: 399-403. 10.1002/ijc.11531.
8. Hopper JL, Chenevix-Trench G, Jolley DJ, Dite GS, Jenkins MA, Venter DJ, McCredie MR, Giles GG: Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr. 1999, 26: 95-100.
9. Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MR, Venter DJ, Hopper JL: Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst. 2003, 95: 448-457.